OR WAIT 15 SECS
The companies will form a biometrics organization focused on delivering analytical solutions for drug development.
Cytel, a provider of analytical software and services to the life sciences industry, and Axio Research, a provider of biostatistics to pharmaceutical, biotechnology, and medical device companies, announced on June 4, 2019 that they have joined forces to create a global biometrics organization focused on delivering analytical solutions for the life sciences industry.
The merged business will operate under the Cytel brand. Axio will continue to provide its data monitoring committee services for clinical trials as “Axio, a Cytel company.” As a merged business, Cytel will consist of 1000 statisticians and data scientists across the United States, India, and Europe. The organization will continue to provide solutions for clinical development while providing services for the combined organization's range of pharmaceutical, biotechnology, and medical devices customers.
“We believe that better use of data will ultimately revolutionize drug development,” said Joshua Schultz, CEO of Cytel, in a company press release. “Our vision is to unite the combined expertise of our two companies to deliver powerful analytical solutions that address trial sponsors’ toughest drug development challenges and maximize the opportunities offered by emerging data sources."
“We are delighted to merge with Cytel, a company that shares our academic heritage, cultural values, and deep commitment to scientific and statistical excellence,” said Lee Hooks, CEO of Axio Research, in the release. “Axio’s capabilities in data monitoring committees and biostatistics services will seamlessly complement Cytel’s existing clinical research services and software. Under the Cytel umbrella, Axio’s customers will receive the same exemplary levels of service while benefiting from extended capabilities, reach, and infrastructure.”